A quarter of a century experience with sleeve lobectomy for non-small cell lung cancer☆

Rea, Federico; Marulli, Giuseppe; Schiavon, Marco; Zuin, Andrea; Hamad, Abdel-Mohsen; Rizzardi, Giovanna; Perissinotto, Egle; Sartori, F

doi:10.1016/j.ejcts.2008.05.027

Cited by 49 publications

(54 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall survival following SL for patients with NSCLC ranges from 39-53% at five years and 28-34% at ten years (4,5,12,16,18,19,23). SL is technically more demanding than PN, and the decision to select this procedure may be influenced by the surgeons' experience.…”

Section: Discussionmentioning

confidence: 99%

“…The presence of N2 significantly impairs long-term outcomes among sleeve lobectomies due to systemic recurrences (16)(17)(18). Furthermore, there were no difference in survival with N0 and N1 disease (17)(18)(19)(20). Comparison between parenchymasparing SL and PN for central T3 NSCLC with absence of N2 disease is the less discussed previously.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

For non-small cell lung cancer with T3 (central) disease, sleeve lobectomy or pneumonectomy?

Ma¹,

Guo²,

Shu³

et al. 2016

J. Thorac. Dis.

View full text Add to dashboard Cite

Background: Pneumonectomy (PN) has traditionally been the treatment of choice for central lung tumors for which the alternative is sleeve lobectomy (SL). The aim of this study was to compare early and long-term results after SL and PN in focusing on T3 central non-small cell lung cancer (NSCLC). Methods:Patients who underwent SL (n=58) or PN (n=42) were retrospectively analyzed. For bias reduction, these 100 patients had been selected according to the following criteria: (I) tumor located in the main bronchus less than 2 cm distal to the carina; (II) there were no N2 disease; (III) no induction therapy was applied; (IV) complete resection (R0) was achieved. It is an adequate oncologic resection and should be treated as the first line intervention whenever complete resection can be achieved.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

For non-small cell lung cancer with T3 (central) disease, sleeve lobectomy or pneumonectomy?

Ma¹,

Guo²,

Shu³

et al. 2016

J. Thorac. Dis.

View full text Add to dashboard Cite

show abstract

“…[8][9][10] Similar results had been reported in the comparison between pneumonectomy and sleeve lobectomy. [11][12][13][14][15] Subgroup analysis had been done in only one study: Luzzi et al reported that no significant survival difference between pneumonectomy and lobectomy for patients with N1 stage NSCLC and level 11 lymph node involvement. 16) On the other hand, a pneumonectomy, especially a right one, includes a higher occurrence of postoperative complications compared to the lobectomy: poorer quality of life, cardiopulmonary dysfunction, and long-term complications.…”

Section: Discussionmentioning

confidence: 99%

Extent of Lung Resection in Non-small Lung Cancer with Interlobar Lymph Node Involvement

Günlüoğlu

Demir

Turna

et al. 2011

ATCS

View full text Add to dashboard Cite

Background: Optimal resection type for non-small cell lung cancer (NSCLC) with interlobar lymph node involvement (ILNI) has seldom been reported. To completely resect a NSCLC with ILNI, some surgeons believe that a pneumonectomy is needed. Methods: We retrospectively studied 151 patients (147 men, 4 women; mean age 58 ± 8 years, range 34-79) with non-small lung cancer without mediastinal or hilar lymph node metastasis who underwent an anatomic lung resection with systematic lymph node dissection between January 1995 and November 2006. All patients had involvement of the surgical-pathologic interlobar (#11) lymph node: 8 patients had a T1 tumor; 95, T2; 39, T3; and 9, T4. We evaluated the effect of resection type (pneumonectomy in 90 patients versus lobectomy in 61) on their prognosis by univariate and multivariate analyses. Results: The 5-year survival rate of patients was 61% for the lobectomy and 35% for the pneumonectomy ( p = 0.04). We did not find statistically significant differences in sex, median age, distributions of tumor site, histology and differentiation, complete resection rate, N1 involvement status, morbidity and mortality. Patients who underwent the pneumonectomy had larger tumors and more T3 tumors. The T status, multiple levels N1 involvement and histology did not affect survival in the univariate analysis. Multivariate analysis revealed resection type as a significant prognostic factor. Conclusions: Pneumonectomy was not necessary in patients with NSCLC and interlobar lymph node involvement that we had discovered intraoperatively.

show abstract

“…Sir Clement Price Thomas is credited with the first bronchial sleeve resection performed for a carcinoid tumour in 1947 at the Brompton Hospital in London, UK. Allison, in 1952, performed a sleeve lobectomy for a lung carcinoma and, in 1955, Paulson and Shaw reported the first comprehensive review on the use of these techniques [1][2][3][4]. At that time, sleeve resections were considered compromised procedures indicated for patients who could not tolerate the pneumonectomy.…”

Section: Introductionmentioning

confidence: 99%

Sleeve lobectomy for patients with non-small-cell lung cancer: a simplified approach

Konstantinou¹,

Potaris²,

Sakellaridis³

et al. 2009

European Journal of Cardio-Thoracic Surgery

View full text Add to dashboard Cite

show abstract

A quarter of a century experience with sleeve lobectomy for non-small cell lung cancer☆

Cited by 49 publications

References 19 publications

For non-small cell lung cancer with T3 (central) disease, sleeve lobectomy or pneumonectomy?

For non-small cell lung cancer with T3 (central) disease, sleeve lobectomy or pneumonectomy?

Extent of Lung Resection in Non-small Lung Cancer with Interlobar Lymph Node Involvement

Sleeve lobectomy for patients with non-small-cell lung cancer: a simplified approach

Contact Info

Product

Resources

About